Last updated on January 2020

Registry on Hypomethylating Agents in Myeloid Neoplasms

Brief description of study

This registry is set up to collect real-world experience in the management of patients with myeloid neoplasms, in particularly in patients with MDS, CMML or AML, treated with hypomethylating agents in Austria and potentially other participating countries. This registry will collect data in a retrospective as well as in a prospective manner at various sites. The aim is to gain valuable insights on both efficacy and toxicity of these drugs in a routine clinical setting in patients with various comorbidities.

Clinical Study Identifier: NCT01595295

Find a site near you

Start Over